会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明申请
    • NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE
    • 制备盐酸杜莫西汀的新方法
    • WO2008107911A2
    • 2008-09-12
    • PCT/IN2008000125
    • 2008-03-05
    • LUPIN LTDSIYAN RAJINDER SINGHGOHEL SUNIL KUMAR VINUBHAISINGH GIRIJ PAL
    • SIYAN RAJINDER SINGHGOHEL SUNIL KUMAR VINUBHAISINGH GIRIJ PAL
    • C07D333/20
    • C07D333/20
    • An improved, safer and easy to operate on plant scale process for synthesis of duloxetine hydrochloride (1) having chiral purity greater than 99.9% that is characterized by the following: (i) preparation of racemic condensed compound (RS)-N,N-di methyl-3- (1-naphthyloxy)-3-(2-thienyl)propanamine (4) by reaction of racemic hydroxy compound (2) with 1-fluronaphthalene (3) in presence of a base such as sodamide, potassium amide or potassium bis(trimethylsilyl)amide (KHDMS) in polar aprotic solvent, (ii) optical resolution of racemic condensed compound (5a + 5b) with di-benzoyl-L-tartaric acid (7, DBTA, R = H) or di-para-anisoyl-L-tartaric acid (7, DATA, R = OCH3) to obtain crude (S)-N.N-dimethyl-3-(1-naphthyloxy)-3-(2-thienyl)propanamine dibenzoyl tartarate salt (8a) or (S)-N.N-dimethyl-3-(1-naphthyloxy)-3-(2-thienyl)propanamine di-p-anisoyl tartarate salt (9a) respectively, (iii) optionally purification of crude tartarate salts (8a or 9a) by crystallization, (iv) optionally purification of duloxetine hydrochloride (1) by crystallization and (v) racemization of undesired (R)-N,N-di methyl-3-(1-naphthyloxy)-3-(2-thienyl)propanamine (5b) by treatment with base potassium bis(trimethylsilyl)amide (KHDMS) to obtain racemic mixture of condensed compounds (5a and 5b). A novel salt S(+)-N.N-dimethyl-3-(1-naphthylenyloxy)-3-(2-thienyl)propanamine dibenzoyl -(L)- tartarate (8a) and S(+)-N.N-dimethyl-3-(1-naphthylenyloxy)-3-(2-thienyl)propanamine di-p-anisoyl-(L)- tartarate (9a). Novel process for racemization of undesired (R)-N,N-di methyl-3-(1-naphthyloxy)-3-(2-thienyl)propanamine (5b) by treatment with KHDMS to obtain racemic mixture condensed compounds (5a and 5b).
    • (1)手性纯度大于99.9%的度洛西汀盐酸盐(1)的合成工艺改进,更安全且易于操作,其特征在于:(i)制备外消旋缩合化合物(RS)-N, 通过使外消旋羟基化合物(2)与1-氟萘(3)在碱如氨基磺酸钠,氨基钾或碱土金属的存在下反应,制备2-甲基-3-(1-萘氧基)-3-(2-噻吩基)丙胺 (二甲基甲硅烷基)氨基钾(KHDMS)在极性非质子溶剂中的溶液,(ii)用二苯甲酰基-L-酒石酸(7,DBTA,R = H)或二 (S)-NN-二甲基-3-(1-萘氧基)-3-(2-噻吩基)丙胺二苯甲酰基酒石酸盐(8a)或(S)-N,N-二甲基-3- (S)-NN-二甲基-3-(1-萘氧基)-3-(2-噻吩基)丙胺二 - 对甲氧基苯甲酰基酒石酸盐(9a),(iii)任选纯化粗酒石酸盐(8a或9a) 通过结晶,(iv)任选纯化 盐酸度洛西汀(1)通过结晶和(v)通过用碱性钾处理不希望的(R)-N,N-二甲基-3-(1-萘氧基)-3-(2-噻吩基)丙胺 (三甲基甲硅烷基)酰胺(KHDMS)以获得缩合化合物的外消旋混合物(5a和5b)。 (+) - NN-二甲基-3-(1-萘基氧基)-3-(2-噻吩基)丙胺二苯甲酰基 - (L) - 酒石酸盐(8a)和S(+) - NN-二甲基-3- (1-萘基氧基)-3-(2-噻吩基)丙胺二 - 对甲氧基苯甲酰基 - (L) - 酒石酸盐(9a)。 用KHDMS处理外消旋不需要的(R)-N,N-二甲基-3-(1-萘氧基)-3-(2-噻吩基)丙胺(5b)的新方法以获得外消旋混合物缩合化合物(5a和5b )。